Gandeeva’s proprietary platform provides a rational, cryo-EM- and AI-driven approach for the design of potent molecular glues.
Gandeeva Therapeutics has raised $40.0M in total funding. The most recent round was Series A. The last funding was announced in January 2022.
Gandeeva Therapeutics's investors include Air Street Capital, Obvious Ventures, Lux Capital, Amplitude Venture Capital, Leaps by Bayer.
Gandeeva Therapeutics is headquartered in Vancouver, Canada.
Gandeeva’s proprietary platform provides a rational, cryo-EM- and AI-driven approach for the design of potent molecular glues.
Gandeeva Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Gandeeva Therapeutics — Funding & Investors." VCBacked, January 31, 2022, https://www.vcbacked.co/company/gandeeva-therapeutics. Accessed November 12, 2026.
VCBacked. (2022). Gandeeva Therapeutics — Funding & Investors. Retrieved November 12, 2026, from https://www.vcbacked.co/company/gandeeva-therapeutics
{{cite web |title=Gandeeva Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/gandeeva-therapeutics |website=VCBacked |access-date=November 12, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Gandeeva Therapeutics? Request a listing update